Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview

Inhibikase Therapeutics

10/08/2026 13:44

Inhibikase Therapeutics, Inc. IKT.OQ IKT.O is expected to  show no change in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Inhibikase Therapeutics, Inc. is for a loss of 11 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Inhibikase Therapeutics, Inc. is $6.00, about 142.9% above its last closing price of $2.47
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.11
-0.11
-0.10
Beat
7.7
Dec. 31 2026
-0.08
-0.10
-0.09
Beat
12.7
Sep. 30 2025
-0.13
-0.13
-0.13
Met
0​
Jun. 30 2025
-0.08
-0.09
-0.11
Missed
-22.2
​​Mar. 31 2025
-0.10
-0.10
-0.17
Missed
-61.9
Dec. 31 2024
-0.09
-0.50
Missed
-476.9​
Sep. 30 2024
-0.38
-0.37
-0.65
Missed
-75.7
Jun. 30 2024
-0.67
-0.67
-0.66
Beat
1.5
This summary was machine generated August 10 at 12:44 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)